Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
about
Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistanceResistance to anti-influenza drugs: adamantanes and neuraminidase inhibitorsExisting antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusionRecent progress in structure-based anti-influenza drug designSafety and efficacy of peramivir for influenza treatmentFunctional and Structural Analysis of Influenza Virus Neuraminidase N3 Offers Further Insight into the Mechanisms of Oseltamivir ResistanceSerendipitous discovery of a potent influenza virus a neuraminidase inhibitorRisk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivirInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceRWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenzaComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spreadHuman-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza virusesEarly pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysisEfficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trialEnvironmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallardsAmino acids transitioning of 2009 H1N1pdm in Taiwan from 2009 to 2011Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling studyInfluenza virus drug resistance: a time-sampled population genetics perspectiveThe N-terminal fragment of a PB2 subunit from the influenza A virus (A/Hong Kong/156/1997 H5N1) effectively inhibits RNP activity and viral replicationResistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.Use of highly pathogenic avian influenza A(H5N1) gain-of-function studies for molecular-based surveillance and pandemic preparedness.Virulence attenuation during an influenza A/H5N1 pandemicOseltamivir (Tamiflu(®)) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans - a reviewTwo years after pandemic influenza A/2009/H1N1: what have we learned?Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.Drug resistance in influenza A virus: the epidemiology and management.Novel strategies for prevention and treatment of influenza.Avian flu: isolation of drug-resistant H5N1 virus.Emergence of drug-resistant influenza virus: population dynamical considerations.Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the DeThe effect of population structure on the emergence of drug resistance during influenza pandemics.Circulating avian influenza viruses closely related to the 1918 virus have pandemic potential.Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble.Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic.Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) VirusesCharacterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations.Zanamivir-resistant influenza viruses with a novel neuraminidase mutationNovel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.
P2860
Q21562135-87FF7082-88F3-4320-AFB3-87EFD6CD5958Q22305941-A154564F-1CCA-4538-837A-979F91A7D7B4Q24536333-F02ECAAC-DBE9-47F3-84DE-C4343A6C62FEQ24656213-F62A3184-DBAE-41D8-B8C7-FA9E1C08C343Q26863710-7DA7A9F6-0CEC-44CD-A90F-DB718BBA7A50Q27027408-1C06CDA9-4BA4-43F7-9D46-04F15ACC9399Q27678914-8B55F833-8FFD-47CA-8001-191C6173D632Q27687973-E13C5721-6E5F-4719-8898-9B0748F59DBCQ28066861-6342B253-13A8-4EEC-841B-0C4F49551E3BQ28282405-2D5AEB5A-AD04-4064-863F-A656BAE4F1A2Q28344592-DAE16523-72EF-4D63-9BB1-5759C7BCFEE7Q28364114-4925855C-98B0-4E87-8DE3-17583787B9A4Q28471814-738FAE4C-102E-47B9-A25C-A5985CE65AF2Q28472513-DF9A1C60-77F0-4A1A-B970-9AA013A57CA8Q28473959-BBE362F2-29E2-445C-8AB2-2F209EE0AE7FQ28475986-D9BF160E-59D9-4C4B-A2F7-A8B19791DC30Q28477046-0798543E-139C-45BE-92E0-BDFB835B07CCQ28483965-0DC45619-CD7C-40E0-84F8-30C56BF41063Q28537982-5F8AE1AE-2FB3-443E-9370-13FE5EAC0837Q28540172-9F0E2F0B-19B2-49F9-8C4D-801BC76DF0B2Q28542440-6C9805D1-95FA-468E-B657-3B1E2CD293EEQ30151772-E151FA16-0F2C-4145-B0CD-3C266F6E229FQ30205712-B068B1F2-178F-42A4-BA78-6398F1E23695Q30223401-511357A6-91B2-4126-BE56-8A74B63EFA2EQ30224096-DFC3819F-562C-455C-8945-4C6E0DAC4D5AQ30224656-A38D9F4A-AD39-47DA-B084-BE44997084E8Q30228322-DF47D4DD-B5F7-4E52-8C88-8BA1F87E78DAQ30234600-EFCC1FE9-188A-4ACD-8283-2B846BEBB92AQ30350342-D635EE0F-182A-4D7C-9B61-804145807FA2Q30351638-AE0149B7-0BDB-4798-85DB-452254944088Q30353989-D1E721BD-3176-410B-8F1F-F249A602868FQ30359034-82AA0266-E97B-4599-8408-2D1A0B102D7AQ30362753-DC401502-D844-47E8-B42D-3821936A5583Q30363524-B09FFF3A-8D27-4211-BF99-A62D4CD3EC48Q30367220-C0D99189-D1DF-48D4-85A8-3DE067CEAACBQ30367643-97BA9F13-C7B3-4431-BBFB-0381F29997DBQ30372421-D2071621-2EA5-4C62-9A06-0992A35D5FF7Q30375636-F269EF0A-6B1B-4D47-A4DE-4873A12D290CQ30379353-C45573D9-E431-488F-8B5A-781C10051919Q30382312-14A61BA0-413A-40CB-96B5-A3E5DEE7BDE0
P2860
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Selection of influenza virus m ...... eers treated with oseltamivir.
@ast
Selection of influenza virus m ...... eers treated with oseltamivir.
@en
type
label
Selection of influenza virus m ...... eers treated with oseltamivir.
@ast
Selection of influenza virus m ...... eers treated with oseltamivir.
@en
prefLabel
Selection of influenza virus m ...... eers treated with oseltamivir.
@ast
Selection of influenza virus m ...... eers treated with oseltamivir.
@en
P2093
P356
P1476
Selection of influenza virus m ...... eers treated with oseltamivir.
@en
P2093
Gubareva LV
Matrosovich MN
P304
P356
10.1086/318537
P407
P577
2001-01-11T00:00:00Z